...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Applied biochemistry and biotechnology, Part A. enzyme engineering and biotechnology >Efficient biocatalyst of L-DOPA with Escherichia coli expressing a tyrosine phenol-lyase mutant from Kluyvera intermedia
【24h】

Efficient biocatalyst of L-DOPA with Escherichia coli expressing a tyrosine phenol-lyase mutant from Kluyvera intermedia

机译：高效的L-DOPA生物催化剂，具有表达来自Kluyvera Impertia的酪氨酸酚类酶突变体的大肠杆菌

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

L-DOPA (L-dihydroxyphenylalanine) is a promising drug for Parkinson's disease and thereby has a growing annual demand. Tyrosine phenol-lyase (TPL)-based catalysis is considered to be a low-cost yet efficient route for biosynthesis of L-DOPA. TPL is a tetrameric enzyme that catalyzes the synthesis of L-DOPA from pyrocatechol, sodium pyruvate, and ammonium acetate. The implementation of TPL for L-DOPA production has been hampered and the need for the most efficient TPL source with higher L-DOPA production and substrate conversion rate is prevailing. This study involves identifying a novel TPL from Kluyvera intermedia (Ki-TPL) and displayed a robust expression in Escherichia coli. The recombinant strain YW000 carrying Ki-TPL proved strong catalytic activity with a highest L-DOPA yield compared with 16 other TPLs from different organisms. With a further aim to improve this efficiency, random mutagenesis of Ki-TPL was performed and a mutant namely YW021 was obtained. The whole cells of YW021 as biocatalyst yielded 150.4 g L-1 of L-DOPA with a 99.99 % of pyrocatechol conversion at the optimum condition of pH 8.0 at 25 degrees C, which is the highest level reported to date. Further, the homology modeling and structural analysis revealed the mutant residues responsible for the extensive L-DOPA biosynthesis.
机译：L-DOPA（L-二羟基苯基丙氨酸）是帕金森病的有希望的药物，从而具有日益增长的年需求。基于苯酚苯酚酶（TPL）的催化被认为是L-DOPA的生物合成的低成本且有效的途径。 TPL是一种四聚酰胺酶，其催化来自PyrocateChol，丙酮酸钠和乙酸铵的L-DOPA的合成。 L-DOPA生产的TPL的实施受到了阻碍，需要具有更高的L-DOPA生产和基板转化率的最有效TPL源的需求。该研究涉及鉴定来自Kluyvera介质（Ki-TPL）的新型TPL，并在大肠杆菌中展示了一种稳健的表达。携带Ki-TPL的重组菌株YW000通过来自不同生物的其他16个其他TPLS，以最高的L-DOPA产率证明了Ki-TPL的强催化活性。进一步旨在提高这种效率，进行Ki-TPL的随机诱变，得到突变的含量。 YW021作为生物催化剂的整个细胞产生150.4g L-1的L-DOPA，99.99％的PyrocateChol转化率在25摄氏度下以pH8.0的最佳条件转化，这是迄今为止报告的最高水平。此外，同源性建模和结构分析揭示了负责广泛的L-DOPA生物合成的突变残留物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号